Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. develops targeted oncology therapies for patients with RAS-addicted cancers. Company news centers on its RAS(ON) inhibitor pipeline, including daraxonrasib, a RAS(ON) multi-selective inhibitor, and selective programs such as elironrasib, zoldonrasib and RMC-5127.
Recurring updates cover clinical data in pancreatic ductal adenocarcinoma, non-small cell lung cancer and other RAS-mutant solid tumors, presentations at oncology meetings, scientific publications, regulatory interactions and trial-stage progress. Revolution Medicines also reports quarterly financial results, financing activity and corporate progress tied to research and development, potential commercialization planning and its broader RAS(ON) discovery platform.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Revolution Medicines, a clinical-stage oncology company focused on targeted therapies for RAS-addicted cancers, will feature CEO Mark A. Goldsmith in a fireside chat at the 22nd Annual Needham Healthcare Conference from April 17-20, 2023. The chat is scheduled for 3:00 p.m. Eastern on April 20, 2023, and will be held virtually with a webcast available. Interested parties can access the live presentation and the subsequent replay on the company’s website for at least 14 days after the event.
The company specializes in developing RAS(ON) Inhibitors aimed at various oncogenic RAS protein variants, with RMC-6236 and RMC-6291 currently in clinical development. Additional pipeline candidates target other RAS mutations and include RAS Companion Inhibitors for combination therapies. For further details, visit Revolution Medicines Events.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced it will present significant preclinical data at the AACR Annual Meeting 2023, taking place from April 14-19, 2023, in Orlando, Florida. Notable presentations include the discovery of RMC-6291, a tri-complex KRAS G12C inhibitor, and RMC-9805, a first-in-class mutant-selective KRAS G12D inhibitor that synergizes with immunotherapy in preclinical models. These innovations aim to address RAS-addicted cancers, showcasing the company's commitment to developing targeted oncological therapies. The presentations are scheduled for April 16 and 17, highlighting advancements in cancer treatment that could significantly impact future clinical strategies.
Revolution Medicines, Inc. (Nasdaq: RVMD) has successfully closed an underwritten public offering, raising $345 million by selling 15,681,818 shares of common stock at a price of $22.00 per share. The underwriters fully exercised their option to purchase additional shares, contributing 2,045,454 shares to the total. The offering was managed by J.P. Morgan, TD Cowen, SVB Securities, and Guggenheim Securities. The registration statement was filed on March 2, 2021, and this transaction is crucial for funding the company's research and development of targeted therapies for RAS-addicted cancers.
Revolution Medicines has announced a public offering of 13,636,364 shares of common stock at $22.00 each, aiming to raise approximately $300 million. All shares are offered by the company, with an additional option for underwriters to purchase up to 2,045,454 shares within 30 days. The offering is expected to close on March 7, 2023. J.P. Morgan, TD Cowen, SVB Securities, and Guggenheim Securities are the joint book-running managers. The funds will support ongoing developments in targeted therapies for RAS-addicted cancers, part of Revolution Medicines' R&D pipeline.